Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men

Massimo Giuliani, Alessandra Latini, Manuela Colafigli, Maria Benevolo, Francesca Rollo, Mauro Zaccarelli, Eugenia Giuliani, Domenico Moretto, Amalia Giglio, Giovanni Rezza, Antonio Cristaudo, Maria G Donà

Research output: Contribution to journalArticle

Abstract

AIM: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.

MATERIALS & METHODS: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.

RESULTS: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.

CONCLUSION: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.

Original languageEnglish
Pages (from-to)1463-1472
Number of pages10
JournalFuture Microbiology
Volume13
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Papillomavirus Infections
Papillomavirus Vaccines
Vaccines
HIV
Sexually Transmitted Diseases
Infection
Vaccination
Population

Cite this

Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men. / Giuliani, Massimo; Latini, Alessandra; Colafigli, Manuela; Benevolo, Maria; Rollo, Francesca; Zaccarelli, Mauro; Giuliani, Eugenia; Moretto, Domenico; Giglio, Amalia; Rezza, Giovanni; Cristaudo, Antonio; Donà, Maria G.

In: Future Microbiology, Vol. 13, 10.2018, p. 1463-1472.

Research output: Contribution to journalArticle

@article{79b3075d74354946a1460d627bf4d9b9,
title = "Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men",
abstract = "AIM: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.MATERIALS & METHODS: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.RESULTS: A total of 49.5 and 71.2{\%} of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.CONCLUSION: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.",
author = "Massimo Giuliani and Alessandra Latini and Manuela Colafigli and Maria Benevolo and Francesca Rollo and Mauro Zaccarelli and Eugenia Giuliani and Domenico Moretto and Amalia Giglio and Giovanni Rezza and Antonio Cristaudo and Don{\`a}, {Maria G}",
year = "2018",
month = "10",
doi = "10.2217/fmb-2018-0149",
language = "English",
volume = "13",
pages = "1463--1472",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men

AU - Giuliani, Massimo

AU - Latini, Alessandra

AU - Colafigli, Manuela

AU - Benevolo, Maria

AU - Rollo, Francesca

AU - Zaccarelli, Mauro

AU - Giuliani, Eugenia

AU - Moretto, Domenico

AU - Giglio, Amalia

AU - Rezza, Giovanni

AU - Cristaudo, Antonio

AU - Donà, Maria G

PY - 2018/10

Y1 - 2018/10

N2 - AIM: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.MATERIALS & METHODS: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.RESULTS: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.CONCLUSION: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.

AB - AIM: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.MATERIALS & METHODS: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.RESULTS: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.CONCLUSION: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.

U2 - 10.2217/fmb-2018-0149

DO - 10.2217/fmb-2018-0149

M3 - Article

VL - 13

SP - 1463

EP - 1472

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

ER -